Aarti Drugs Intrinsic Value
Aarti Drugs intrinsic value. Aarti Drugs (AARTIDRUGS) median intrinsic value is ₹373.89 from 10 valuation models (range ₹125–₹634), vs current price ₹415.00 — -9.9% downside (Trading Near Calculated Value), margin of safety -11.0%. For current market price and key ratios, visit Aarti Drugs share price screener.
AARTIDRUGS Valuation Methods Summary — DCF, Graham Number & P/E
Aarti Drugs intrinsic value across 10 models vs current price ₹415.00 — upside/downside and value range per method. Read AARTIDRUGS ex-dividend dates for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹532.40 | ₹425.92 - ₹638.88 | +28.3% | EPS: ₹24.20, Sector P/E: 22x |
| Book Value Method | asset | ₹340.44 | ₹306.40 - ₹374.48 | -18.0% | Book Value/Share: ₹170.22, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹633.85 | ₹570.47 - ₹697.24 | +52.7% | Revenue/Share: ₹316.92, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹426.37 | ₹383.73 - ₹469.01 | +2.7% | EBITDA: ₹388.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹379.14 | ₹303.31 - ₹454.97 | -8.6% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹154.88 | ₹139.39 - ₹170.37 | -62.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹373.89 | ₹336.50 - ₹411.28 | -9.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹290.11 | ₹261.10 - ₹319.12 | -30.1% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹304.44 | ₹274.00 - ₹334.88 | -26.6% | EPS: ₹24.20, BVPS: ₹170.22 |
| Dividend Yield Method | dividend | ₹124.50 | ₹112.05 - ₹136.95 | -70.0% | DPS: ₹2.00, Target Yield: 2.5% |
AARTIDRUGS Intrinsic Value vs Market Price — All Valuation Models
Aarti Drugs fair value range ₹125–₹634 vs current market price ₹415.00 across 10 valuation models. Compare with AARTIDRUGS fair value to assess whether the stock is under or overvalued.
AARTIDRUGS Intrinsic Value Analysis — Undervalued or Overvalued?
Aarti Drugs median intrinsic value ₹373.89, current price ₹415.00 — Trading Near Calculated Value by 9.9%, margin of safety -11.0%.
What is the intrinsic value of AARTIDRUGS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Aarti Drugs (AARTIDRUGS) is ₹373.89 (median value). With the current market price of ₹415.00, this represents a -9.9% variance from our estimated fair value.
The valuation range spans from ₹124.50 to ₹633.85, indicating ₹124.50 - ₹633.85.
Is AARTIDRUGS undervalued or overvalued?
Based on our multi-method analysis, Aarti Drugs (AARTIDRUGS) appears to be trading near calculated value by approximately 9.9%.
AARTIDRUGS Financial Health — Key Ratios vs Industry Benchmarks
Aarti Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.27 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.02x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
AARTIDRUGS Cash Flow Quality — Operating & Free Cash Flow
Aarti Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹254 Cr | ₹168 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹245 Cr | ₹163 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹359 Cr | ₹247 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹133 Cr | ₹51 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹70 Cr | ₹-5 Cr | Positive Operating Cash Flow | 6/10 |